Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 190
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast
BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
PT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic...
HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S....
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access...
Trauma and Vulnerability to Suggestion: Redefining How We Understand Consent
COMPASS Pathways plc to announce fourth quarter and full year 2021...
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through...
Awakn Files Patent For A New Class Of Entactogen-Like Molecules
Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism
Load more